美泊利珠单抗治疗重度嗜酸性哮喘的真实世界疗效与超应答者特征
伴鼻息肉、较低基线ACQ-6、较低BMI及较低基线泼尼松龙剂量与更好应答相关。
要点
- 美泊利珠单抗治疗1年急性发作减少54%,57%可停用维持口服激素。
- 合并鼻息肉、较低BMI、较低基线ACQ-6及较低泼尼松龙剂量与更好应答相关。
- 24周时可识别92.9%患者的一年应答状态。
核心结论
- 真实世界重度嗜酸性哮喘队列中,美泊利珠单抗减少急性发作频率和维持口服激素需求。
- 鼻息肉、较低BMI及较低基线维持泼尼松龙需求与更好结局相关。
- 24周时可识别超过90%患者的一年应答状态。
研究设计与样本
- 每4周采集临床数据,在第16、24、52周将患者分类为应答者或非应答者。
主要发现
- 72.7%(95%CI 63.0–80.7)归类为应答者,28.3%(95%CI 20.2–38.0)归类为超应答者。
- 第16周时可正确识别80.8%患者的一年应答状态,第24周时升至92.9%。
关键数值与推荐
- 应答定义为急性发作减少≥50%;使用维持口服激素者,应答定义为泼尼松龙剂量减少≥50%。
- 超应答定义为1年时无急性发作且停用维持口服激素。
临床怎么用
- 对重度嗜酸性哮喘患者,美泊利珠单抗可在真实世界减少急性发作并降低维持口服激素需求。
- 基线伴鼻息肉、较低BMI、较低ACQ-6及较低泼尼松龙剂量者更可能获得良好应答。
- 可在第24周评估一年应答状态,以辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mepolizumab was the first licensed anti-IL5 monoclonal antibody for severe eosinophilic asthma (SEA). To date there are few data to confirm its efficacy in the real-world setting or assessment of baseline characteristics associated with response. RESEARCH QUESTION: How do patients with severe eosinophilic asthma respond to mepolizumab in the real world setting and which characteristics are associated with a super-response to this therapy? STUDY DESIGN AND METHODS: We conducted a retrospective review of all patients who received at least 16 weeks of treatment with mepolizumab (100 mg subcutaneously) for SEA at our regional asthma center in the United Kingdom. Clinical data were collected at each 4-week visit. At 16, 24, and 52 weeks, patients were classified as "responders" or "nonresponders." A response was defined as ≥50% reduction in exacerbations; for patients whose condition requires maintenance oral corticosteroids (mOCS), a response was defined as ≥50% reduction in prednisolone dose. Super responders were defined as exacerbation-free and off mOCS at one year. RESULTS: Ninety-nine patients were included in the analysis. Asthma exacerbations decreased from a baseline of 4.04 ± 2.57 to 1.86 ± 2.17 per year at one year (54% reduction; P < .001). Sixty-eight patients were receiving mOCS at the time of commencing mepolizumab. By one year, the daily median dose fell from 10 mg (interquartile range, 10 to 15) to 0 mg (interquartile range, 0 to 10; P < .001). Fifty-seven percent of them were able to discontinue mOCS; 72.7% (95% CI, 63.0 to 80.7) of the patients were classified as responders, and 28.3% (95% CI, 20.2 to 38.0) of the patients were classified as super responders. Baseline characteristics associated with responder and super responder status included the presence of nasal polyposis (P = .012), lower baseline Asthma Control Questionnaire 6 (P = .006), a lower BMI (P = .014), and, in those patients receiving mOCS, a significantly lower prednisolone dose at baseline (P = .005). At 16 weeks, the one-year responder status was correctly identified in 80.8% patients; by 24 weeks, this status rose to 92.9%. INTERPRETATION: In a real-world SEA cohort, treatment with mepolizumab reduced exacerbation frequency and mOCS requirements. Nasal polyposis, a lower BMI, and a lower maintenance prednisolone requirement at baseline were associated with better outcomes. Twelve-month response was identifiable in >90% of patients by week 24.
引用
- Kavanagh JE, d'Ancona G, Elstad M, et al. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Chest. 2020. PMID: 32275980. doi:10.1016/j.chest.2020.03.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。